SLENYTO NEWS

Dear Partners,

We are delighted to share with you the latest SLENYTO® news as part of our common efforts towards a successful launch;

Slenyto long term data paper has been accepted by JCAP

We are proud to announce that a publication on SLENYTO® Phase III clinical study long term results was accepted to Journal of child and adolescence psychopharmacology (JCAP). JCAP is a premier peer reviewed Journal covering the clinical aspects of treating this patient population with psychotropic medications. This is another step in building the scientific foundations and background to support SLENYTO® penetration.
Click here for more information on JCAP.

Slenyto Phase III results were presented at a DGSM conference in Germany

SLENYTO® Phase III results were presented for the first time at a local conference in Germany. Infectopharm invited Dr. Athanasios Maras (The Netherlands) to present SLENYTO® phase III results at the Spring Conference of the Pediatrics Working Group of the DGSM (German Society for Sleep Research and Sleep Medicine)
Dr Maras presented the results in a poster and in a 45 min lecture at a lunch symposium. The symposium generated a lot of interest with 110 attendees.

Upcoming events:

Vast activities were planned this year at pivotal conferences, as part of SLENYTO® educational plan and on-going efforts to engage with leading KOLs in the field toward the Launch of SLENYTO®.

  • PedPRM Global Advisory Board April 13th, Madrid. Leading KOLs from France, Germany, Spain, UK, US already confirmed their attendance.
    The objectives of the meeting:

    • To understand the path of diagnosis and management of Pediatric ASD Insomnia.
    • To understand the importance and the challenges of treating Pediatric ASD Insomnia and its impact on patients, families and society from physicians point of view.
    • To understand the place of PedPRM within the treatment paradigm of Pediatric ASD Insomnia.
  • SLENYTO® Brand meeting May 8, Rotterdam, The Netherlands.
  • INSAR (International Society for Autism Research), May 9-12, Rotterdam, The Netherlands.
    • Oral abstract presentation “Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder”. Saturday, May 12, 2018, 1:45 PM
    • Medical Information Booth. Reprints of Gringras, 2017 and poster with short and long- term results will be available at the booth.

Looking forward to continuing introduction of SLENYTO® to the local markets and see you and your clients participating in further International events!

  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.
    • Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland
    • Circadin is celebrating 10 years in market!
  • Partners

    Partners